Please provide your email address to receive an email when new articles are posted on . In 2026, Stelara will be discounted 66% from its list price for Medicare users, while Enbrel will be discounted ...
Stelara (ustekinumab) is a prescription drug that treats autoimmune conditions such as plaque psoriasis. You typically inject it subcutaneously (under your skin) or receive it intravenously (directly ...
Evernorth's Accredo specialty pharmacy will offer biosimilars for the popular immunotherapy Stelara at $0 for eligible patients, the company announced Thursday. The interchangeable biosimilar will be ...
In May 2025, the FDA approved numerous biosimilars as interchangeable with Stelara ® (ustekinumab) and Humira ® (adalimumab), bringing the total number of Stelara ® interchangeables to four, plus an ...
This news release contains certain forward-looking statements relating to STARJEMZA ® /BAT2206 or the product pipelines in general of Bio-Thera Solutions and Hikma. Readers are strongly cautioned that ...
Alternative pharmacy benefit manager Serve You Rx is seeking to generate additional savings for its clients by adding two biosimilars for the popular drug Stelara to its formulary. The PBM will add ...
STEQEYMA is indicated for the treatment of plaque psoriasis (PsO) and psoriatic arthritis (PsA) in adult and pediatric patients, as well as Crohn's disease (CD) and ulcerative colitis (UC) in adult ...
The MarketWatch News Department was not involved in the creation of this content. -- Steqeyma(R) (CT-P43), is now approved in Canada for adult patients with plaque psoriasis as well as adults with ...
GUANGZHOU, China and LONDON, May 27, 2025 /PRNewswire/ -- Bio-Thera Solutions, Ltd (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of biosimilars and innovative assets ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results